ACL Laboratories
Now part of ADVOCATEHEALTH

Test Bulletin

September 2025

Phenylalanine Monitoring, Plasma

Effective Wednesday, September 17, 2025, Phenylalanine Monitoring, Plasma (Test Order Code LAB12620) has been deactivated. Test available within existing panel Phenylalanine and Tyrosine (Test Older Code LAB12621).

Tyrosine

Effective Wednesday, September 17, 2025, Tyrosine (Test Order Code LAB9866) has been deactivated. Test available within existing panel Phenylalanine and Tyrosine (Test Order Code LAB12621).

New Orderable Code: Heparin Induced Thrombocytopenia - PEA

Effective Wednesday, September 17, 2025, Heparin-Induced Thrombocytopenia - PEA (Test Order Code LAB13003) is available as an orderable test with testing being performed at Versiti Laboratory. The test information is below.

Test Information	Heparin Inducted Thrombocytopenia - PEA
Specimen Requirement	Two 5.0 mL (minimum 1.5 mL) aliquots of serum
Collection Tube	Two plain red
Temperature	Refrigerated
Stability	7 days
Methodology	Flow Cytometry
TAT	Final within 4 days
Performing Lab	Versiti

Updated Referral Testing Orderable Code

Effective Wednesday, September 17, 2025, the following send out assays have a collection requirement update.

- Test Order Code LAB9812 – Selenium, Plasma
- Test Order Code LAB9452 – Cobalt, Serum
- Test Order Code LAB9440 – Chromium, Serum
- Test Order Code LAB9335 – Aluminum, Serum
- Test Order Code LAB9716 – Nickel, Serum

Specimen Preparation: Centrifuge the tubes to separate the serum or plasma form the cells within 2 hours. **Carefully pour directly into Metal Free Transport Tube avoiding transfer of the cellular components of blood.** Transport tubes are available through the normal supply ordering process.

For additional information regarding these tests, as well as specimen collection requirements, please contact ACL Client Services at 1.800.877.7016 or visit our website at https://www.acllaboratories.com/providers/test-directory/.

continued...

Created: 9/2025 | Created by: H. Barrie – ACL Business Development | Designed by: C. McDonough – Graphic Designer
CM-HB-2509a

Effective Wednesday, September 17, 2025, the following send out assays have been updated.

Bicarbonate, Urine		
	Former (Deactivated 9/17/2025)	**Current (Activated 9/17/2025)**
Test Name	Bicarbonate, Urine	Bicarbonate, Urine
Test Order Code	LAB9387	LAB13016
Performing Lab	ARUP	ARUP
Specimen Type	Urine	1.0 mL (minimum 0.3 mL) Urine
Collection container	Sterile container	Sterile container
Temperature	Frozen	Refrigerated
Stability	1 month	30 days
Methodology	Quantitative Enzymatic Assay	Quantitative Enzymatic Assay
TAT	Final within 4 days	Final within 11 days

Insulin-Like Growth Factor-1, Pediatric with Z-Score by LC-MS		
	Former (Deactivated 9/17/2025)	**Current (Activated 9/17/2025)**
Test Name	Insulin-Like Growth Factor-1, Pediatric with Z-Score by LC-MS	Insulin-Like Growth Factor-1, Pediatric with Z-Score by LC-MS
Test Order Code	LAB12655	LAB13103
Performing Lab	Mayo	Mayo
Specimen Type	Serum	0.5 mL (0.3 mL minimum), serum
Collection container	Gold Gel	Red top
Temperature	Frozen	Refrigerated
Stability	4 weeks	7 days
Methodology	Liquid Chromatography/Mass Spectrometry	Liquid Chromatography/Mass Spectrometry
TAT	Final within 6 days	Final within 10 days

For additional information regarding these tests, as well as specimen collection requirements, please contact ACL Client Services at 1.800.877.7016 or visit our website at https://www.acllaboratories.com/providers/test-directory/.

continued...

Created: 9/2025 | Created by: H. Barrie – ACL Business Development | Designed by: C. McDonough – Graphic Designer CM-HB-2509a

Cytomegalovirus by Qualitative PCR, Select Sources		
	Former (Deactivated 9/17/2025)	**Current (Activated 9/17/2025)**
Test Name	Cytomegalovirus by Qualitative PCR on FFPE Tissue	Cytomegalovirus by Qualitative PCR, Select Sources
Test Order Code	LAB11542	LAB13041
Performing Lab	ARUP	ARUP
Specimen Type	Formalin-fixed, paraffin-embedded tissue (FFPE)	**This orderable code is to be used for these specific sources:** • Formalin-fixed, paraffin-embedded tissue (FFPE) • 1.0 ml (0.5 mL minimum) Ocular Fluid, Amniotic fluid OR Cerebrospinal Fluid (CSF) • Tissue • 1.0 mL (0.5 mL minimum) Bone Marrow
Collection container	Formalin-fixed, paraffin-embedded tissue (FFPE)	• Formalin-fixed, paraffin-embedded tissue (FFPE)- Testing may be performed on FFPE Tissue to perform testing order ADD ON PATHOLOGY (Test Order Code LAB9054) • Ocular Fluid, Amniotic fluid OR Cerebrospinal Fluid (CSF)- Sterile container • Tissue- Sterile container • Bone Marrow- Lavender (K2EDTA) tube
Temperature	Ambient	• Formalin-fixed, paraffin-embedded tissue (FFPE)- **Ambient** • Ocular Fluid, Amniotic fluid OR Cerebrospinal Fluid (CSF) - **Frozen** • Tissue- **Frozen** • Bone Marrow- **Frozen**
Stability	3 months	• Formalin-fixed, paraffin-embedded tissue (FFPE)- 3 months • Ocular Fluid, Amniotic fluid OR Cerebrospinal Fluid (CSF) – 3 months • Tissue- 3 months • Bone Marrow-1 week
Methodology	Qualitative Polymerase Chain Reaction (PCR)	Qualitative Polymerase Chain Reaction (PCR)
TAT	Final within 5 days	Final within 5 days

For additional information regarding these tests, as well as specimen collection requirements, please contact ACL Client Services at 1.800.877.7016 or visit our website at https://www.acllaboratories.com/providers/test-directory/.

continued...

Created: 9/2025 | Created by: H. Barrie – ACL Business Development | Designed by: C. McDonough – Graphic Designer CM-HB-2509a

Herpes Simplex Virus (HSV-1/HSV-2) Subtype by PCR, Select Sources		
	Former (Deactivated 9/17/2025)	**Current (Activated 9/17/2025)**
Test Name	HSV-1 HSV-2 Subtype by PCR on FFPE Tissue	Herpes Simplex Virus (HSV-1/HSV-2) Subtype by PCR, Select Sources
Test Order Code	LAB11541	LAB13042
Performing Lab	ARUP	ARUP
Specimen Type	Formalin-fixed, paraffin-embedded tissue (FFPE)	**This orderable code is to be used for these specific sources:** • Formalin-fixed, paraffin-embedded tissue (FFPE) • 1.0 ml (0.5 mL minimum) Ocular Fluid, Amniotic fluid OR Cerebrospinal Fluid (CSF) • 1.0 ml (0.5 mL minimum) Bronchoalveolar Lavage (BAL) OR Bronchial Washing • Tissue • Endocervical
Collection container	Formalin-fixed, paraffin-embedded tissue (FFPE)	• Formalin-fixed, paraffin-embedded tissue (FFPE)- Testing may be performed on FFPE Tissue to perform testing order ADD ON PATHOLOGY (Test Order Code LAB9054) • Ocular Fluid, Amniotic fluid OR Cerebrospinal Fluid (CSF)- Sterile container • Bronchoalveolar Lavage (BAL) OR Bronchial Washing - Sterile Container • Tissue- Sterile container • Endocervical - ThinPrep Pap test vial
Temperature	Ambient	• Formalin-fixed, paraffin-embedded tissue (FFPE)- **Ambient** • Ocular Fluid, Amniotic fluid OR Cerebrospinal Fluid (CSF) - **Frozen** • Bronchoalveolar Lavage (BAL) OR Bronchial Washing - **Frozen** • Tissue- **Frozen** • Endocervical- **Frozen**
Stability	3 months	• Formalin-fixed, paraffin-embedded tissue (FFPE)- 3 months • Ocular Fluid, Amniotic fluid OR Cerebrospinal Fluid (CSF) – 3 months • Bronchoalveolar Lavage (BAL) OR Bronchial Washing- 3 months • Tissue- 3 months • Endocervical- 3 months
Methodology	Qualitative Polymerase Chain Reaction (PCR)	Qualitative Polymerase Chain Reaction (PCR)
TAT	Final within 5 days	Final within 5 days

For additional information regarding these tests, as well as specimen collection requirements, please contact ACL Client Services at 1.800.877.7016 or visit our website at https://www.acllaboratories.com/providers/test-directory/.

continued...

Created: 9/2025 | Created by: H. Barrie – ACL Business Development | Designed by: C. McDonough – Graphic Designer CM-HB-2509a

Method Change for Cystatin C with Estimated Glomerular Filtration Rate

Effective Thursday, September 18, 2025, the testing method for Cystatin C with Estimated Glomerular Filtration Rate (Test Order Code LAB10964) transitioned from a nephelometric method to a turbidimetric method.

Note the following updates associated with this transition in the chart below.

Estimated Glomerular Filtration Rate (Test Order Code LAB10964)			
	Former Nephelometric Method	**Current Turbidimetric Method – Effective 9/18/2025**	**Note regarding Turbidimetric Method**
Turnaround Time (TAT)	24 hours	72 hours	Testing will be performed weekdays
Analytical Measurement Range (AMR)	0.05–8.0 mg/L	0.4–5.6 mg/L	Endpoint dilution will be performed for results over 5.6 mg/L
Reference Range	0.50–1.00 mg/L	0.55–1.00 mg/L	

D Dimer Reference Range Update

Effective Thursday, September 18, 2025.

Evaluation of D Dimer has multiple uses in healthcare and will be elevated anytime fibrin forming a clot is broken down in the peripheral blood. Our previous D Dimer reference range was based on healthy patient standards; however, different reference ranges can be used in different clinical settings.

Due to the majority of tests ordered to evaluate for a DVT with concern for pulmonary emboli, ACL adjusted the reference range to <0.50 mg/L (FEU). This value will also continue to include a comment on how to calculate cut-offs for excluding patients of different ages in the appropriate setting.

All tests should be ordered and interpreted in the context of the patient being evaluated and the clinical setting.

Summary of the change identified below: Reference Range

D Dimer Reference Range		
Test	**Former Reference Range**	**Current Reference Range (Effective 9/18/2025)**
D Dimer Quantitative (Test Order Code LAB8427)	<0.57 mg/L (FEU)	<0.50 mg/L (FEU)

For additional information regarding these tests, as well as specimen collection requirements, please contact ACL Client Services at 1.800.877.7016 or visit our website at https://www.acllaboratories.com/providers/test-directory/.

continued...

Created: 9/2025 | Created by: H. Barrie – ACL Business Development | Designed by: C. McDonough – Graphic Designer CM-HB-2509a

ACL Discontinues Streptococcus Group B PCR (Test Order Code LAB9032)

Effective Wednesday, October 15, 2025, ACL will discontinue the test Streptococcus Group B PCR (Test Order Code LAB9032). Maternal antepartum screening for Group B Streptococcus (GBS) will continue to be offered using bacterial culture and can be ordered using test Streptococcus Group B, Bacterial Culture (Test Order Code LAB9003).

ACL will discontinue this test due to low test utilization, alignment with current national testing standards, and the availability of a suitable alternative (Streptococcus Group B, Bacterial Culture). Of the over 18,000 GBS screening tests ordered annually within the Advocate Health Midwest Region, less than 5% of the tests are performed by PCR, while the remainder are performed using culture. Utilization of culture for antepartum GBS screening in pregnant women remains the current standard and is endorsed by the American College of Obstetricians and Gynecologists, the American College of Nurse-Midwives, the American Academy of Pediatrics, the Centers for Disease Control and Prevention and the American Society of Microbiology.

Test Name	Streptococcus Group B PCR (Test Order Code LAB9032)	Streptococcus Group B, Bacterial Culture (Test Order Code LAB9003)
Specimen Source	Vaginal/Rectal swab	Vaginal/Rectal Swab
Collection Device	White capped ESwab	White capped ESwab
Stability	Ambient: 72 hours Refrigerated: Unacceptable Frozen: Unacceptable	Ambient: 72 hours Refrigerated: Unacceptable Frozen: Unacceptable
Turnaround Time	Final within 3 days	Final within 3 days

Clostridioides difficile Test Algorithm Change

Effective Wednesday, October 15, 2025, ACL Laboratories will implement a change to the primary testing methodology for *Clostridioides difficile*. The laboratory previously utilized Polymerase Chain Reaction (PCR) as the primary screening test for detection of *C. difficile* bacteria with PCR positive specimens automatically reflexing to an Enzyme Immunoassay (EIA) test to identify the presence of the *C. difficile* toxin protein. The laboratory will transition away from the PCR plus toxin EIA algorithm to an EIA test that will simultaneously detect and report the presence of both *C. difficile* bacteria (previously detected by PCR) and *C. difficile* toxin protein.

The new testing algorithm is less likely to detect patients colonized with *C. difficile*, which is expected to decrease overtreatment of colonized patients. In addition to decreasing overtreatment, the updated *C. difficile* testing algorithm will lead to standardized *C. difficile* testing approaches, treatment guidelines, isolation approaches, and reporting of Hospital-Acquired Infections (HAI) to the National Healthcare Safety Network (NHSN) across the entire Advocate Health Enterprise. The decision to change *C. difficile* testing algorithms has been a highly collaborative effort and has included: The laboratory Infectious Diseases Technical Advisory Team, Infectious Disease Providers, Infection Prevention and Antimicrobial Stewardship.

The new test *C. difficile* EIA (Test Order Code LAB12930) will be the primary test available for diagnosis of *C. difficile* and will continue to be performed on site at all Advocate Health hospitals and within the two Central Microbiology Laboratories within the Midwest region. The test will be used to simultaneously detect the presence of the *C. difficile* bacterial antigen and the presence of *C. difficile* toxin protein via EIA. Both the *C. difficile* antigen and toxin EIA results will be reported for all patients.

The PCR test will continue to be offered, at least temporarily, within the two Central Microbiology Laboratories. However, the test will ***only*** be orderable by laboratory team members and will require a phone call to ACL Client Services to add-on the testing.

Please contact Eric Beck, Clinical Laboratory Director – Microbiology, eric.beck@aah.org with any additional questions.

For additional information regarding these tests, as well as specimen collection requirements, please contact ACL Client Services at 1.800.877.7016 or visit our website at https://www.acllaboratories.com/providers/test-directory/.

Created: 9/2025 | Created by: H. Barrie – ACL Business Development | Designed by: C. McDonough – Graphic Designer CM-HB-2509a